Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-HEXA Antibody (R3A01)

Catalog #:   RHC22201 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2b
Applications: ELISA, FCM, WB
Accession: P06865
Overview

Catalog No.

RHC22201

Species reactivity

Human

Host species

Mouse

Isotype

IgG2b

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, WB: 1:500-1:2000

Target

Beta-hexosaminidase subunit alpha, HEXA, Beta-N-acetylhexosaminidase subunit alpha, Hexosaminidase subunit A, N-acetyl-beta-glucosaminidase subunit alpha

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P06865

Applications

ELISA, FCM, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3A01

Data Image
  • Flow Cytometry
    Flow cytometric analysis of HeLa cells using HEXA mouse mAb (green) and negative control (red).
  • Western blot
    Western blot analysis using HEXA mouse mAb against L1210 (1), and HL7702 (2) cell lysate.
References

Bifidobacteria support optimal infant vaccine responses., PMID:40175554

HEXA-FC protein therapy increases skeletal muscle glucose uptake and improves glycaemic control in mice with insulin resistance and in a mouse model of type 2 diabetes., PMID:40156616

Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses., PMID:40063739

Novel paper sensor with modified aptamer for accurate detection of clinical cardiac troponin I., PMID:39998327

Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial., PMID:38857311

Quantitative, compositional, and immunohistochemical analyses of chondroitin sulfate, dermatan sulfate, and hyaluronan in internal organs of deer (Cervus nippon centralis and C. n. yesoensis) and cattle (Bos taurus)., PMID:38281521

Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism., PMID:38214443

Pseudorabies gD protein protects mice and piglets against lethal doses of pseudorabies virus., PMID:38029147

Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from Mycobacterium tuberculosis challenge., PMID:37903877

Tdap vaccine in pregnancy and immunogenicity of pertussis and pneumococcal vaccines in children: What is the impact of different immunization schedules?, PMID:37816653

AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques., PMID:37783968

Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age., PMID:37202270

Production and applications of fluorobody from redox-engineered Escherichia coli., PMID:36729226

A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients., PMID:36545777

A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine., PMID:36476534

Analysis of Brain Lipids in the Early-Onset Tay-Sachs Disease Mouse Model With the Combined Deficiency of β-Hexosaminidase A and Neuraminidase 3., PMID:36003081

6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice., PMID:35711416

One-step-immunoassay of procalcitonin enables rapid and accurate diagnosis of bacterial infection., PMID:35478797

Dissecting in Vitro the Activation of Human Immune Response Induced by Shigella sonnei GMMA., PMID:35186786

Expression and purification of a native Thy1-single-chain variable fragment for use in molecular imaging., PMID:34845270

Hexavalent vaccines: What can we learn from head-to-head studies?, PMID:34531081

Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection., PMID:34362603

Investigating Immune Responses to the scAAV9-HEXM Gene Therapy Treatment in Tay-Sachs Disease and Sandhoff Disease Mouse Models., PMID:34201771

CREG1 promotes lysosomal biogenesis and function., PMID:33966596

Lipid A Structural Divergence in Rickettsia Pathogens., PMID:33952661

Human Hexa-Histidine-Tagged Single-Chain Variable Fragments for Bioimaging of Bacterial Infections., PMID:33458528

A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against Klebsiella pneumoniae Serotype K2., PMID:33108196

Dengue and Zika virus multi-epitope antigen expression in insect cells., PMID:32997310

Elucidating the difference in the kinetics of antibody titres of infants in Belgium and Vietnam., PMID:32933790

Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers., PMID:32888740

SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques., PMID:32817214

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants., PMID:32750261

Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial., PMID:32448624

Protection and Safety Evaluation of Live Constructions Derived from the Pgm- and pPCP1- Yersinia pestis Strain., PMID:32098032

Reshaping nanobodies for affinity purification on protein a., PMID:32001339

Group A Streptococcus Cell Wall Oligosaccharide-Streptococcal C5a Peptidase Conjugates as Effective Antibacterial Vaccines., PMID:31872763

Comparative Structural Study of Terminal Ends of Lipoarabinomannan from Mice Infected Lung Tissues and Urine of a Tuberculosis Positive Patient., PMID:31762254

Viral antigen nanoparticles for discriminated and quantitative detection of different subtypes of anti-virus immunoglobulins., PMID:31573015

Computationally Designed Peptides for Zika Virus Detection: An Incremental Construction Approach., PMID:31533374

Semisynthetic Glycoconjugate Vaccines To Elicit T Cell-Mediated Immune Responses and Protection against Streptococcus pneumoniae Serotype 3., PMID:31126171

Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection., PMID:30670300

Production and characterization of recombinant P1 adhesin essential for adhesion, gliding, and antigenic variation in the human pathogenic bacterium, Mycoplasma pneumoniae., PMID:30551878

Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease., PMID:30220252

A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model., PMID:29861179

IgG-single-chain TRAIL fusion proteins for tumour therapy., PMID:29773864

Performance of point-of-care diagnosis of AIDS: label-free one-step-immunoassay vs. lateral flow assay., PMID:29363681

Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months., PMID:29333947

A Hexa-rhodium Metallopeptide Catalyst for Site-Specific Functionalization of Natural Antibodies., PMID:28810739

Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development., PMID:28665620

Neoglycoconjugate of Tetrasaccharide Representing One Repeating Unit of the Streptococcus pneumoniae Type 14 Capsular Polysaccharide Induces the Production of Opsonizing IgG1 Antibodies and Possesses the Highest Protective Activity As Compared to Hexa- and Octasaccharide Conjugates., PMID:28626461

Datasheet

Document Download

Anti-HEXA Antibody (R3A01).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-HEXA Antibody (R3A01) [RHC22201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only